Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 1,746,822 shares, a growth of 27.5% from the November 30th total of 1,369,590 shares. Approximately 11.7% of the shares of the company are short sold. Based on an average daily volume of 1,900,662 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily volume of 1,900,662 shares, the days-to-cover ratio is presently 0.9 days. Approximately 11.7% of the shares of the company are short sold.

Immix Biopharma Stock Down 4.2%

Shares of NASDAQ IMMX opened at $5.28 on Wednesday. The firm’s 50-day simple moving average is $4.61 and its 200 day simple moving average is $3.18. The stock has a market cap of $177.30 million, a P/E ratio of -6.86 and a beta of 0.33. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $7.73.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). On average, sell-side analysts anticipate that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Immix Biopharma by 4.5% in the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after acquiring an additional 31,625 shares in the last quarter. Susquehanna International Group LLP raised its stake in shares of Immix Biopharma by 78.8% in the 3rd quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after purchasing an additional 40,032 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Immix Biopharma in the 3rd quarter valued at about $188,000. United Capital Financial Advisors LLC bought a new stake in shares of Immix Biopharma in the third quarter valued at about $148,000. Finally, Imprint Wealth LLC acquired a new position in shares of Immix Biopharma during the third quarter worth about $141,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. HC Wainwright raised their price target on Immix Biopharma from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Wall Street Zen raised shares of Immix Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.00.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.